Friday, 15 November 2019

BioLargo Reports Solid Operating Results in Third Quarter as it Breaks Revenue Records


Revenue grew 93% compared with third quarter 2018.

Revenue grew 53% compared with nine-months 2018

Quarter over quarter revenues averaging a 25% increase for the past 3 years

New PFAS solution confirms efficacy



Westminster, CA – November 15, 2019 – BioLargo, Inc. (OTCQB:BLGO) (“the Company”), developer of sustainable products and a full-service environmental engineering company, today announced the filing of its 10-Q quarterly report for the third quarter of 2019. Company management encourages its stockholders to review the quarterly report at www.biolargo.com/sec-filings.

Highlights from the Quarterly Report:
  • Combined revenues from BioLargo’s operating units during the third quarter of 2019 grew 93% over the third quarter of 2018 to $534,000.
  • Combined revenues from BioLargo’s operating units during the nine months of 2019 grew 53% over 2018 to $1,324,000.
  • Revenues represent more than 25% average quarter-over-quarter growth over last 3 years.
  • Engineering division showed operating profit in third quarter for first time since inception in 2017.

Highlights for Subsidiaries

Odor-No-More
  • Revenues for the nine months ended September 30, 2019 increased $227,000 (29%) from the same period in 2018. Revenue for the three months ended September 30, 2019, increased $150,000 (61%) compared to the same period in 2018.
  • Signed a Memorandum of Understanding with BKT Co. Ltd, a major wastewater treatment solutions provider in South Korea and its US-based subsidiary Tomorrow Water. The MOU represents the formation of a strategic alliance aimed at exploring opportunities for our technologies in the water and wastewater industry of South Korea, with an initial focus on opportunities for CupriDyne® Clean.
  • Secured first customers in the cannabis and hemp industry and sales are ramping up through our distributor.

BioLargo Engineering
  • BLEST’s revenues grew 385% in the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2019.
  • BLEST’s revenues grew 284% in the three months ended September 30, 2019 as compared to the third quarter of 2018.
  • In Q3, BLEST showed an operating profit for the first time since its inception two years ago.
  • BLEST developed an innovative technology with support from an EPA grant that eliminates per- and poly-fluoroalkyl substances (PFAS) from water.
  • Now serving seven US Air Force bases as part of “Teaming Agreements” with Bhate Environmental Associates with 8 additional bids in various stages of process for potentially 25 additional bases.

Clyra Medical Technologies
  • FDA 510(k) pre-market clearance received September 2019 for Clyra’s Wound Irrigation Solution, designed for cleansing, irrigating, and debriding dermal wounds and burns, in addition to moistening absorbent wound dressings.
  • Formed a “Medical Advisory Board” of more than 30 physicians, surgeons and key opinion leaders.


BioLargo Water
  • Poultry farm pre-commercial field pilot was successful, and has led to a request by the client for a full-scale commercial trial for BioLargo’s patented AOS water treatment platform.
  • Stormwater treatment AOS pilot was officially launched at facility in Southern California.

President and CEO Dennis P. Calvert commented, “We achieved record sales and improved our cash and debt position. We secured FDA 510(k) clearance for our first Clyra medical product and executed successful demonstration pilots for our AOS clean water technology. We watched BioLargo Engineering, with the support from an EPA grant, obtain proof-of-claim evidence for what we believe will become a low cost and high-performance solution to the PFAS water contamination crisis that industry and government are desperate to solve. Our mission is to combine powerful technology with unparalleled talent to create and deliver complete solutions to some of the toughest issues that affect the world, and in this quarter we had significant success in advancing this mission.”


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert President and CEO BioLargo, Inc. 888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Wednesday, 13 November 2019

BioLargo CEO Interviewed at The Wall Street Resource



Westminster, CA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioLargo (OTCQB: BLGO), developer of sustainable technologies and full-service environmental engineering, announced today that its President & CEO Dennis P. Calvert was interviewed by The Wall Street Resource, a platform for microcap company news and due diligence. The interview can be accessed here: https://thewallstreetresource.com/webcasts/.

Mr. Calvert’s interview highlighted several of BioLargo’s innovative clean tech products and services. In particular, Mr. Calvert gave an update on the development of the company’s new water treatment technology designed to address per- and poly-fluoroalkyl substances (PFAS), a class of water contaminants of growing concern in the US.

The interview with Mr. Calvert was published at 2:00 p.m. PST on November 13, 2019.  The interview webcast is free of cost to all listeners and available at www.thewallstreetresource.com. In addition, the interview will be available for replay.

About Biolargo (BLGO) 
BioLargo invents, patents, and develops innovative platform technologies for three markets: 1) advanced water and wastewater treatment, 2) industrial odor and VOC control, and 3) advanced wound care products. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity.  BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies. 

About The Wall Street Resource
The Wall Street Resource.com is a platform for microcap discovery and due diligence. It's your resource for webcast interviews of CEOs and executives. For more information, please visit: www.thewallstreetresource.com

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information
Dennis P. Calvert, President & CEO of BioLargo, Inc. 
888-400-2863

Tuesday, 12 November 2019

BioLargo, Inc. Updates the Stock Day Podcast on Quarterly Growth, Commercialization, and Its Role in Solving the PFAS Crisis

Source: Newsfile Corp.



Phoenix, Arizona--(Newsfile Corp. - November 12, 2019) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. President & CEO BioLargo, Dennis P. Calvert, joined Stock Day host Jamie Fellows.
Fellows began the interview by asking Mr. Calvert for an update on BioLargo's revenue growth and balance sheet. Calvert explained that the company will be publishing their quarterly report in just a few days. "The revenues for the quarter will come in at just about $500,000, which is another record for the company."
Calvert then expanded on BioLargo's progress in improving its balance sheet. "Just a few months ago, we were able to restructure short-term debt into long-term debt," explained Calvert. "We were also able to pay off and retire about $1.2 million in what the industry refers to as variable-priced debt. That's a big deal," said Calvert. He further explained that the company has followed an aggressive investment strategy, which is now paying off. "All of the fruits of these investments are now panning out," said Calvert. "I think it's a very exciting time for the company."
Fellows asked Mr. Calvert about the EPA grant that BioLargo Engineering was recently awarded to help solve the growing issue of PFAS (per- and poly-fluoroalkyl substances) contamination. Calvert explained that PFAS water contamination is a widespread problem because these chemicals are found in a vast number of household and industrial products and don't break down easily in nature. They are also linked to adverse health effects. "As a result, there is a big crisis," said Calvert. "People are finding that our groundwater is contaminated with PFAS," said Calvert.
Mr. Calvert then commented on the technology they developed as a result of the US EPA grant they were awarded. "We have proven claims that we're getting at least 99% reduction [from water] in a single pass," explained Calvert. "We're busy with patents, we're busy with scale-ups, and we're in discussion with major partnerships," said Calvert. "We've got the talent in-house to support this technology."
Mr. Calvert also answered questions about BioLargo's wound care subsidiary, Clyra Medical Technologies. "Clyra Medical just got its first FDA clearance, just a few weeks ago, for its first advanced wound care product," shared Calvert. "With that product, we can continue to focus on extraordinarily high-value assets," he continued. "Now what we're focused on is building that infrastructure, getting clinical [trials], and slowly entering the market," said Calvert.
Mr. Calvert closed the interview by saying, "We think the future for BioLargo is exceptionally exciting and it's a great time to take a look at this company."
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President & CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
602-441-3474

Monday, 4 November 2019

BioLargo Spotlight: Odor-No-More Tackling Odors at Larva Factory

BioLargo’s subsidiary Odor-No-More has made a name for itself mainly by selling its industry-best odor and VOC control product CupriDyne® Clean to the waste handling industry – meaning landfills, transfer stations, composting facilities, etc. As last week’s blog post demonstrates that the company is also expanding into new market applications like the cannabis and hemp industry. What most people might not realize, however, is that the company’s odor and VOC control products and services can help in virtually any situation where nuisance odors are causing problems for a company. Today’s blog post illustrates this idea by highlighting an interesting facility that Odor-No-More is now serving.

The company’s newest odor control client – Vivotein – operates soldier fly larva factories in Southern California, and they were having tough odor control challenges that are now being solved by CupriDyne Clean.

If you’re reading this, there’s a good chance you might be asking what a soldier fly is. Soldier flies are small black flies whose larvae (about the size and appearance of a mealworm) have a wide variety of uses for humans, including as an animal feed, fishing bait, and composting supplement.

The Vivotein facility in Ontario, CA, now being serviced by Odor-No-More, produces huge quantities of soldier fly larvae mainly for use as an animal feed, and the final packaged larvae must be dehydrated before shipment. The larvae are dehydrated in enormous ovens which creates a strong and distinct odor. Out of respect for their neighbors and in a desire to stay ahead of the curve in the area of odor control, the Ontario Vivotein facility decided to implement Odor-No-More’s odor control system because of our recognition as an industry-leading odor solution provider. Now, plant management reports that odor emissions from the building have been reduced substantially.

The first equipment installed by Odor-No-More were on the facility’s exhaust vents (see video below) to directly address the odor emissions that leave the building. Next, in the second phase of equipment installation, Odor-No-More is installing odor elimination equipment at key locations throughout the facility. These delivery systems were designed, built, and installed all by Odor-No-More staff.


Waste handling remains the company’s primary target market. There is a seemingly endless number of landfills, transfer stations, and composting facilities that need high performance odor control products and systems, and in the coming weeks we’ll be bringing you more posts that discuss projects at waste handling sites. We hope that this week’s post helps demonstrate that Odor-No-More’s odor and VOC control products have the potential to address odor problems across a vast range of industries. As we like to say – there’s no odor problem we can’t help solve.

Was this blog post helpful, informative, or interesting? Let us know on social media at:


What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.  

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.

Tuesday, 29 October 2019

BioLargo Spotlight: Cannabusters Finding Traction in Cannabis and Hemp Industry, Increasing Sales with Unmatched Performance


Pumps used for one Cannabusters Install
BioLargo’s distribution partner for the cannabis and hemp industry, Cannabusters, Inc., continues to land new accounts for our odor and VOC control product! We signed a white label distribution agreement with Cannabusters  to sell CupriDyne® Clean to customers in the cannabis and hemp cultivation industry under the brand name “Cannabusters”. Our partner’s investments in marketing and trade shows across North America are clearly paying off, as the product is beginning to gain traction in the market as industry players are recognizing our product as an effective, eco-friendly, and affordable solution to the odor and VOC control problem in the industry. Since we announced the first Cannabusters sales just a few short weeks ago, the number of accounts for the product in the cannabis and hemp industry has grown to seven and counting.

Cannabusters (www.thecannabusters.com) is selling our white label odor and VOC control products  as well as design, construction, and installation services for product delivery systems as needed. The customers love the product because it’s easy to use and it frequently exhibits odor reduction rates of 90%+, while being eco-friendly and non-toxic. This isn’t surprising given the fact that the product has been demonstrated through third-party laboratory testing to reduce odor-causing terpenes by almost 100%. This fact is a key component in Cannabusters’ ongoing marketing campaign targeting large cannabis and hemp cultivators and processors in the US.
Misting ring for Cannabusters dispersal

As you can see in the image to the right, Cannabusters is frequently deployed through misting rings attached to greenhouses’ exhaust fans. This way, the product is misted through the air that leaves the greenhouse, neutralizing the odor of the air leaving the facility.

Rooftop vent equipped with odor elimination system
Odor-No-More President Joseph Provenzano commented on the growing sales of Cannabusters, “Our products are finding traction in the cannabis industry because they work. Cannabusters’ investments in marketing and product positioning throughout the U.S. and Canada are paying off, and we are thankful for their efforts that are yielding results. As sales of our products grow in this market, we will continue to refine our modeling of potential revenues for our white label cannabis and hemp odor and VOC control products.”

Was this blog post helpful, informative, or interesting? Let us know on social media at:
Twitter: @BioLargo


What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.  

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.


Monday, 21 October 2019

BioLargo Spotlight: Clyra Team Convenes Newly Formed Medical Advisory Board at Symposium for Advanced Wound Care (SAWC) to Plan Clinical Trials and Commercial Roll-out of First Product



Last week, executive management of BioLargo’s subsidiary Clyra Medical Technologies met for the first time with the company’s newly formed Medical Advisory Board to discuss clinical trials, refine the company’s strategy for commercialization, and plan for development of additional products. This meeting comes in the wake of Clyra’s recently announced FDA 510(k) approval for its first advanced wound care product, a wound irrigation product based on the company’s proprietary antimicrobial chemistry.

The Medical Advisory Board meeting took place at the Fall 2019 Symposium for Advanced Wound Care (SAWC) in Las Vegas, a leading forum for the advancement of wound care practices and technology now in its 33rd year. The event was attended by thousands of physicians, researchers, scientists, podiatrists, wound care technology experts, and more.

Clyra’s Medical Advisory Board is comprised of over 30 experts, including medical doctors, surgeons, podiatrists, wound care researchers, and medical industry experts. Members of Clyra’s Medical Advisory Board offer Clyra unprecedented insight into the science and business of clinical wound care and provide invaluable counsel to Clyra as it prepares its first product for clinical trials and commercialization following its recent FDA approval.

To see Clyra’s Medical Advisory Board and learn about its members, visit https://www.clyramedical.com/advisoryboard 
Clyra's President Steve Harrison comments on the Medical Advisory Board meeting, “We are pleased that we have been able to attract some of the best and brightest minds in diverse fields relevant to our powerful and innovative wound care products. Our Advisory Board includes world-renowned experts in wound care, infection research, orthopedic surgery, podiatry, medical product development, reimbursement and more. We look forward to a long and productive relationship with these world-class advisors, and we know our Advisory Board will play a big role in the successful commercial rollout of our advanced wound care products. Our first meeting at SAWC was a huge step toward achieving that goal”.





About Clyra Medical Technologies, Inc.
Clyra Medical Technologies, Inc., a subsidiary of BioLargo, Inc., develops best-in-class advanced wound care products designed to promote fast, effective wound healing without sacrificing tissue health or sensitivity. Clyra’s first product, a wound irrigation solution, received pre-market approval through FDA 510(k) in September, 2019. The company also owns SkinDiscTM, a revolutionary stem cell therapy product that provides unprecedented wound healing with no documented adverse reactions. Learn more at www.clyramedical.com

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.com) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert 
President and CEO 
BioLargo, Inc. 
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Thursday, 10 October 2019

Proactive investors interview: BioLargo reaches 'critical mass' and reports record-breaking revenue ahead of 3Q earnings

Source: Proactive Investors



BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive Investors the California-based technology developer and environmental engineering company has achieved record-breaking quarterly revenue, disclosed in a release ahead of its 3Q earnings report.

Calvert says the growth was driven by huge increases in its Odor-No-More and engineering divisions. The company expects third-quarter revenue of about $500,000, up nearly 90% year-over-year and 23% quarter-over-quarter.